【摘 要】
：
目的 To analyze the clinical features of hemorrhagic cystitis (HC) , risk factors and treatment strategies about the related HLA-haploidentical non T cell-depleted in vitro peripheral hematopoietic stem
【出 处】
：
中华医学会血液学分会第九次全国造血干细胞移植学术会议
论文部分内容阅读
目的 To analyze the clinical features of hemorrhagic cystitis (HC) , risk factors and treatment strategies about the related HLA-haploidentical non T cell-depleted in vitro peripheral hematopoietic stem cell transplantation (RHNT-PSCT).
其他文献
Immunopathogenesis of GVHD Central role of CD4+ T cells in GVHD Recent studies on Th22/IL-22 in GVHD Administration of IL-22 enhanced thymus recovery in mouse after total body irradiation.(Science 201
Leukemia remains a serious disease with high morbidity and mortality Elizabeth W,et al.CA Cancer J Clin.2014 Cornelissen JJ,et al.Blood,2007allo-HSCT is an effective treatment for leukemia Allo-HSCT t
Background During the last years, hematopoietic stem cell transplant from haploidentical donor is increasing by using the unmanipulated graft.We report an update of the results of allogeneic bone marr
Background Ph+ ALL is a high-risk subset of ALL that has an extremely poor prognosis Since the introduction of TKI to combination chemotherapy regimens, the majority of newly diagnosed Ph+ ALL patient
Background PT =PLT≤80 × 109/L,w/recovery of other cell count w/o apparent cause of thrombocytopenia Kim DH,et al.J Korean Med Sci,2006,21(1);46-51Kim DH et al.Bone Marrow Transplant,2006,37(1): 101-10
目的 GVHD iis the major complication after allogeneic BMT.VPA has been described as a HDAC inhibitor which had anti-inflammatory effects and could reduce the production of pro-inflammatory cytokines in
目的 探讨监测WT1基因对急性髓系白血病(AML)及骨髓增生异常综合征(MDS)患儿进行异基因造血干细胞移植(allo-HSCT)后的临床意义.方法 本文回顾性分析了2009年1月至2012年12月在我单位行allo-HSCT、且移植后连续监测WT1基因至少1年的36例儿童AML/MDS患者.留取移植后+30、+60、+90、+180、+270、+360天、+18月、+24月、+30月、+36月骨
目的 In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia (CML) in chronic or accelerated phase.Although second-generation TKIs (TKI2
目的 探讨IDA-BUCY2强化预处理异基因造血干细胞移植(allo-HSCT)治疗难治复发性急性髓系白血病(AML)的有效性及安全性.方法 对2004年10月至2015年3月于我院行allo-HSCT的66例难治复发性AML患者进行回顾性分析,44例采用IDA-BUCY2强化预处理方案,22例采用改良BUCY2方案,比较两组移植后急慢性移植物抗宿主病(GVHD)、复发率、移植相关死亡率(TRM)
目的 观察并分析挽救性造血干细胞移植治疗高危、难治和复发恶性血液病的有效性和安全性.方法 回顾性分析2013年3月至2015年4月在我院接受挽救性造血干细胞移植的高危、难治和复发恶性血液病患者的临床资料.共有70例患者,中位年龄24岁(1岁～51岁),男性49例,女性21例.患急性髓系白血病31例,骨髓增生异常综合征转白9例,急性淋巴细胞白血病22例,高危骨髓增生异常综合征5例,慢性粒细胞白血病加